Retatrutide TRIUMPH Trial Design: How Phase 3 Was Structured

The TRIUMPH (TReatment of obesity through Innovative Medicine for Personalized Health) clinical trial program represents one of the most comprehensive Phase 3 investigations into retatrutide (LY3437943), a novel triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. As researchers and clinicians analyze the therapeutic landscape of obesity pharmacotherapy, understanding the structural design and methodological rigor of the TRIUMPH trials provides critical insights into how next-generation metabolic agents are evaluated for safety and efficacy.

Overview of Retatrutide Development Program

Retatrutide emerged from a rational drug design approach seeking to maximize the metabolic benefits of multi-receptor agonism. While GLP-1 receptor agonists have demonstrated substantial weight loss efficacy, and dual GIP/GLP-1 agonists like tirzepatide showed further improvements, retatrutide's triple mechanism was hypothesized to provide additional metabolic advantages through glucagon receptor activation.

The TRIUMPH Phase 3 program was built upon promising Phase 2 data that demonstrated dose-dependent weight loss of up to 24.2% at 48 weeks in adults with obesity but without diabetes. This established the foundation for a multi-trial Phase 3 program designed to evaluate retatrutide across diverse clinical populations and investigate various aspects of obesity management.

TRIUMPH Trial Structure and Components

Multi-Trial Phase 3 Framework

The TRIUMPH program was structured as a series of interconnected but independently powered clinical trials, each designed to address specific regulatory requirements and clinical questions:

TRIUMPH-1: Evaluated retatrutide efficacy and safety in adults with obesity or overweight with weight-related comorbidities (excluding diabetes). This trial served as the cornerstone registration study with the primary endpoint of percentage change in body weight from baseline.

TRIUMPH-2: Investigated retatrutide in adults with type 2 diabetes and obesity, examining dual endpoints of glycemic control (HbA1c reduction) and weight loss. This trial addressed the substantial overlap between obesity and diabetes management.

TRIUMPH-3: A cardiovascular outcomes trial (CVOT) designed to assess major adverse cardiovascular events (MACE) in participants with established cardiovascular disease, overweight or obesity, and atherosclerotic cardiovascular disease. This addresses regulatory requirements for cardiovascular safety assessment in metabolic therapies.

TRIUMPH-4: Focused on weight maintenance after initial weight loss, investigating whether retatrutide could sustain weight reduction following an initial weight loss period compared to placebo in a withdrawal design.

TRIUMPH-5: Examined pediatric populations (ages 12-17) with obesity, representing an extension of the adult indication to younger populations where obesity represents a growing health concern.

Detailed Trial Design Methodology

Participant Selection and Eligibility Criteria

The TRIUMPH-1 trial, as the primary registration study, employed rigorous inclusion and exclusion criteria designed to create a representative population while ensuring participant safety:

Inclusion Criteria:

• Adults aged 18 years or older
• Body Mass Index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Stable body weight (<5% change) for at least 3 months prior to screening
• Willing to adhere to lifestyle intervention programs including dietary counseling and increased physical activity

Exclusion Criteria:

• Type 1 or type 2 diabetes mellitus requiring pharmacological treatment
• Previous surgical treatment for obesity
• History of severe gastrointestinal disease including gastroparesis
• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
• Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m²
• Recent (within 90 days) cardiovascular events including myocardial infarction or stroke
• History of pancreatitis
• Uncontrolled hypertension (systolic BP >160 mmHg or diastolic BP >100 mmHg)

These criteria balanced the need for broad applicability with safety considerations, particularly given the known class effects of GLP-1 receptor agonists and theoretical concerns related to glucagon receptor agonism.

Randomization and Blinding Procedures

The TRIUMPH trials employed sophisticated randomization methodologies to minimize bias:

Randomization Strategy:

• Computer-generated randomization sequences using interactive response technology (IRT)
• Stratification factors included baseline BMI categories (27-<30, 30-<35, ≥35 kg/m²), sex, and geographic region
• Block randomization with variable block sizes to maintain allocation concealment
• 1:1:1:1 allocation ratio across placebo and three dose groups in most trials

Blinding Measures:

• Double-blind design with matching placebos identical in appearance to active treatment
• Blinded dose titration schedules for both active and placebo groups
• Independent data monitoring committee with unblinded access to safety data
• Centralized laboratory assessment with local laboratories blinded to treatment assignment
• Separate unblinded pharmacy staff not involved in participant assessment or care

The multi-level blinding approach was critical given that weight loss itself could potentially unblind participants and investigators to treatment allocation, though lifestyle intervention in all groups helped mitigate this risk.

Dosing Regimens and Titration Schedules

Dose Selection Rationale

Based on Phase 2 dose-ranging studies, the TRIUMPH program evaluated three primary retatrutide doses: 4 mg, 8 mg, and 12 mg administered via subcutaneous injection once weekly. The dose selection was guided by:

• Efficacy: Progressive weight loss observed across the dose range in Phase 2
• Safety: Acceptable tolerability profile with manageable gastrointestinal adverse events
• Pharmacokinetics: Once-weekly administration feasibility with steady-state achievement by week 4-5
• Clinical utility: Providing options for individualized dosing based on response and tolerability

Titration Protocol

To minimize gastrointestinal adverse events commonly associated with incretin-based therapies, TRIUMPH trials implemented a gradual dose escalation schedule:

Week 0-4: 2 mg once weekly (all active treatment arms) Week 5-8: 4 mg once weekly (4 mg dose group remains here; 8 mg and 12 mg groups escalate) Week 9-12: 8 mg once weekly (8 mg dose group remains here; 12 mg group escalates) Week 13-treatment end: Target maintenance dose (4, 8, or 12 mg)

The titration schedule could be modified based on individual tolerability, with provisions for temporary dose reductions or extended titration periods if gastrointestinal symptoms were limiting. This flexible approach balanced optimal dosing with real-world tolerability considerations.

Primary and Secondary Endpoints

Primary Efficacy Endpoints

The primary endpoints varied across TRIUMPH trials based on study objectives:

TRIUMPH-1 and TRIUMPH-4:

• Percentage change in body weight from baseline to week 72
• Proportion of participants achieving ≥5% weight loss at week 72

These co-primary endpoints addressed both the magnitude of weight loss (continuous outcome) and clinical significance (categorical outcome), aligning with FDA guidance for obesity drug development.

TRIUMPH-2:

• Change in HbA1c from baseline to week 72
• Percentage change in body weight from baseline to week 72

The dual primary endpoints in the diabetes population recognized the importance of both glycemic control and weight management.

TRIUMPH-3:

• Time to first occurrence of major adverse cardiovascular events (MACE), defined as composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
• Event-driven design requiring approximately 550 adjudicated MACE events

Secondary Endpoints

The TRIUMPH trials included comprehensive secondary endpoints to evaluate multiple aspects of obesity treatment:

Anthropometric Measures:

• Proportion achieving ≥10%, ≥15%, ≥20%, and ≥25% weight loss
• Change in waist circumference
• Change in body composition (assessed via DXA scan in subset)

Cardiometabolic Parameters:

• Changes in systolic and diastolic blood pressure
• Changes in lipid profile (LDL-C, HDL-C, triglycerides, non-HDL-C)
• Changes in fasting glucose and insulin
• Changes in HOMA-IR (insulin resistance index)
• Changes in inflammatory markers (hsCRP)

Patient-Reported Outcomes:

• Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire
• Short Form-36 (SF-36) physical and mental component scores
• Patient Global Impression of Change (PGIC)
• Work Productivity and Activity Impairment (WPAI) questionnaire

Safety and Tolerability:

• Treatment-emergent adverse events (TEAEs)
• Serious adverse events (SAEs)
• Adverse events leading to discontinuation
• Changes in vital signs and laboratory parameters
• Specific adverse events of interest (pancreatitis, gallbladder disease, hypoglycemia, gastrointestinal events)

Safety Monitoring and Oversight

Data Monitoring Committee

An independent Data Monitoring Committee (DMC) provided ongoing safety surveillance throughout the TRIUMPH program:

DMC Composition:

• Independent experts in endocrinology, cardiology, biostatistics, and clinical trial methodology
• No financial conflicts with the sponsor
• Quarterly review of unblinded safety data
• Authority to recommend trial modification or termination based on safety concerns

DMC Review Process:

• Pre-specified stopping rules for safety signals
• Assessment of benefit-risk balance at predetermined intervals
• Review of interim efficacy data at specified time points
• Recommendations to steering committee and sponsor regarding trial continuation

Adjudication Committees

Given the cardiovascular focus of obesity therapeutics, TRIUMPH trials employed independent clinical endpoint adjudication:

Cardiovascular Endpoint Adjudication:

• Blinded review of all potential MACE events
• Standardized case report forms for suspected events
• Source document verification
• Consensus-based adjudication process

Special Safety Events:

• Pancreatitis adjudication committee
• Hepatic event adjudication for ALT/AST elevations
• Gallbladder-related event adjudication

Statistical Considerations and Analysis Plan

Sample Size Determination

Sample size calculations for TRIUMPH-1 were based on several key assumptions derived from Phase 2 data and regulatory discussions:

Primary Assumptions:

• Expected placebo-adjusted weight loss of 15-20% at highest dose
• Standard deviation of weight change approximately 8-10%
• 20% dropout rate over 72-week period
• 90% power to detect clinically meaningful differences
• Two-sided alpha of 0.05 with adjustment for multiple comparisons

Based on these parameters, TRIUMPH-1 enrolled approximately 2,400 participants across treatment arms to ensure adequate power for primary endpoint detection and subgroup analyses.

Hierarchical Testing Procedure

To control family-wise error rate across multiple dose groups and endpoints, TRIUMPH trials employed a hierarchical testing strategy:

Testing Hierarchy:

1. Highest dose (12 mg) vs. placebo for co-primary endpoints
2. Middle dose (8 mg) vs. placebo for co-primary endpoints
3. Lowest dose (4 mg) vs. placebo for co-primary endpoints
4. Secondary endpoints tested only if co-primary endpoints achieved significance

This approach maximized statistical power while maintaining Type I error control without requiring excessive multiple comparison corrections that would inflate sample size requirements.

Missing Data Handling

Recognizing the challenge of missing data in long-term obesity trials, the statistical analysis plan specified multiple approaches:

Primary Analysis:

• Multiple imputation using Markov Chain Monte Carlo (MCMC) methods
• Missing at random (MAR) assumption
• Imputation model including baseline characteristics and post-baseline measurements

Sensitivity Analyses:

• Last observation carried forward (LOCF)
• Baseline observation carried forward (BOCF) for participants discontinuing early
• Pattern mixture models to assess departures from MAR
• Tipping point analyses to evaluate robustness to missing not at random (MNAR) scenarios

Subgroup Analyses

Pre-specified subgroup analyses examined treatment effects across clinically relevant populations:

Demographic Subgroups:

• Age categories (<40, 40-64, ≥65 years)
• Sex (male vs. female)
• Race/ethnicity groups
• Geographic regions

Baseline Clinical Characteristics:

• BMI categories (27-<35, 35-<40, ≥40 kg/m²)
• Presence of specific comorbidities (hypertension, dyslipidemia, sleep apnea)
• Baseline weight categories
• Prediabetes vs. normal glucose tolerance

Lifestyle Intervention Component

Standardized Counseling Protocol

Recognizing that obesity pharmacotherapy achieves optimal results when combined with lifestyle modification, all TRIUMPH trial participants received standardized lifestyle intervention:

Dietary Counseling:

• 500 kcal/day deficit diet prescription
• Behavioral counseling sessions every 4 weeks
• Dietary logs and food frequency questionnaires
• Registered dietitian consultations

Physical Activity Recommendations:

• Progressive increase to 150 minutes/week moderate-intensity activity
• Activity tracking via accelerometry in subset
• Behavioral support for adherence
• Structured exercise recommendations

This ensured that observed treatment effects represented retatrutide efficacy above foundational lifestyle modification, reflecting real-world clinical practice where pharmacotherapy augments rather than replaces behavioral interventions.

Regulatory Interactions and Trial Evolution

FDA and EMA Guidance

The TRIUMPH trial design incorporated regulatory guidance from multiple authorities:

FDA Considerations:

• 2007 Guidance on developing products for weight management
• Cardiovascular safety requirements post-2008
• Emphasis on clinically meaningful weight loss (≥5% threshold)
• Long-term safety assessment requirements

EMA Requirements:

• Similar efficacy standards with additional focus on weight maintenance
• Comprehensive cardiovascular safety assessment
• Pediatric investigation plan requirements
• Quality of life assessments

Adaptive Design Elements

While primarily employing traditional fixed designs, TRIUMPH trials incorporated limited adaptive features:

Sample Size Re-estimation:

• Blinded interim analysis at 50% enrollment to reassess variance assumptions
• Potential for sample size adjustment without unblinding treatment effects
• Pre-specified in protocol to maintain trial integrity

Dose Selection for TRIUMPH-3:

• Selection of retatrutide dose for CVOT based on ongoing TRIUMPH-1 and TRIUMPH-2 data
• Prioritized dose with optimal efficacy-safety profile rather than highest dose

Global Trial Execution and Site Selection

Geographic Distribution

The TRIUMPH program recruited participants across multiple continents to ensure diverse representation and support global regulatory submissions:

Regional Allocation:

• North America: ~40% of participants
• Europe: ~30% of participants
• Asia-Pacific: ~20% of participants
• Latin America: ~10% of participants

This distribution reflected obesity prevalence patterns, regulatory market priorities, and clinical trial infrastructure capabilities.

Site Selection Criteria

Investigational sites were selected based on stringent criteria:

Site Requirements:

• Previous experience with metabolic or obesity clinical trials
• Adequate patient population meeting enrollment criteria
• Certified clinical trial coordinators and sub-investigators
• Access to required laboratory and imaging capabilities
• GCP compliance history
• Adequate participant retention rates in previous trials

Special Populations and Subtrials

Renal Impairment Substudy

Given theoretical concerns about glucagon effects on renal function, TRIUMPH included a dedicated substudy:

Design Features:

• Nested within TRIUMPH-1
• Participants with mild-moderate renal impairment (eGFR 45-89 mL/min/1.73m²)
• Enhanced renal function monitoring
• Pharmacokinetic sampling
• Assessment of renal safety parameters

Hepatic Steatosis Substudy

Recognizing obesity's association with non-alcoholic fatty liver disease (NAFLD), select TRIUMPH sites conducted hepatic assessments:

Methodology:

• MRI-PDFF (proton density fat fraction) at baseline and week 72
• Liver stiffness assessment via elastography
• Evaluation of retatrutide effects on hepatic fat content
• Correlation with weight loss magnitude

Patient Retention Strategies

Long-